Decreased expression of liver-type fatty acid-binding protein is associated with poor prognosis in hepatocellular carcinoma

Hepato-Gastroenterology

Volumn 61, Issue 133, 2014, Pages 1321-1326

  Wang, Bin ^a   Tao, Xuan ^a   Huang, Chuan Zhong ^a   Liu, Jing Feng ^a   Ye, Yun Bin ^a   Huang, Ai Min ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma (hcc); Immunohistochemistry; L FABP; Real time RT PCR; Tissue microarray

Indexed keywords

FATTY ACID BINDING PROTEIN; LIVER TYPE FATTY ACID BINDING PROTEIN; UNCLASSIFIED DRUG; FABP1 PROTEIN, HUMAN; MESSENGER RNA; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; ONCOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TUMOR INVASION; TUMOR VOLUME; CASE CONTROL STUDY; CHEMISTRY; GENETICS; KAPLAN MEIER METHOD; LIVER TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; TIME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; DOWN-REGULATION; FATTY ACID-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, MESSENGER; TIME FACTORS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84906972446     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge13960     Document Type: Article

References (28)

1. Schroeder F, Jolly CA, Cho TH, Frolov A: Fatty acid binding protein isoforms: structure and function. Chem Phys Lipids 1998;92:1-25. (Pubitemid 28236431)
2. Furuhashi M, Hotamisligil GS: Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 2008;7:489-503. (Pubitemid 351767117)
3. Sorof S: Modulation of mitogenesis by liver fatty acid binding protein. Cancer Metastasis Rev 1994;13:317-36.
4. Rajaraman G, Burczynski FJ: Effect of dexamethasone, 2-bromopalmitate and clofibrate on L-FABP mediated hepatoma proliferation. J Pharm Pharmacol 2004;56:1155-61. (Pubitemid 39207195)
5. Tolle A, Suhail S, Jung M, Jung K, Stephan C: Fatty acid binding proteins (FABPs) in prostate, bladder and kidney cancer cell lines and the use of IL-FABP as survival predictor in patients with renal cell carcinoma. BMC Cancer 2011;11:302.
6. Pelsers MM, Namiot Z, Kisielewski W, Namiot A, Januszkiewicz M, Hermens WT, et al.: Intestinal-type and liver-type fatty acid-binding protein in the intestine. Tissue distribution and clinical utility. Clin Biochem 2003;36:529-35. (Pubitemid 37244015)
7. Richieri GV, Ogata RT, Zimmerman AW, Veerkamp JH, Kleinfeld AM: Fatty acid binding proteins from different tissues show distinct patterns of fatty acid interactions. Biochemistry 2000;39:7197-204. (Pubitemid 30413109)
8. Li H, Lu Q, Dong LH, Xue H, Zhou HY, Yang HJ: (Expression of fatty acid binding protein in human breast cancer tissues). Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2007;23:312-6.
9. Hammamieh R, Chakraborty N, Barmada M, Das R, Jett M: Expression patterns of fatty acid binding proteins in breast cancer cells. J Exp Ther Oncol 2005;5:133-43. (Pubitemid 41739373)
10. Das R, Hammamieh R, Neill R, Melhem M, Jett M: Expression pattern of fatty acid-binding proteins in human normal and cancer prostate cells and tissues. Clin Cancer Res 2001;7:1706-15. (Pubitemid 32708639)
11. Hashimoto T, Kusakabe T, Watanabe K, Sugino T, Fukuda T, Nashimoto A, et al.: Liver-type fatty acid-binding protein is highly expressed in intestinal metaplasia and in a subset of carcinomas of the stomach without association with the fatty acid synthase status in the carcinoma. Pathobiology 2004;71:115-22. (Pubitemid 38437705)
12. Kawamura T, Kanno R, Fujii H, Suzuki T: Expression of liver-type fatty-acid-binding protein, fatty acid synthase and vascular endothelial growth factor in human lung carcinoma. Pathobiology 2005;72:233-40. (Pubitemid 43004466)
13. Lawrie LC, Dundas SR, Curran S, Murray GI: Liver fatty acid binding protein expression in colorectal neoplasia. Br J Cancer 2004;90:1955-60. (Pubitemid 38746336)
14. Pei H, Zhu H, Zeng S, Li Y, Yang H, Shen L, et al.: Proteome analysis and tissue microarray for profiling protein markers associated with lymph node metastasis in colorectal cancer. J Proteome Res 2007;6:2495-501. (Pubitemid 47122346)
15. Kheirelseid EA, Miller N, Chang KH, Nugent M, Kerin MJ: Clinical applications of gene expression in colorectal cancer. J Gastrointest Oncol 2013;4:144-57.
16. Dong LH, Li H, Wang F, Li FQ, Zhou HY, Yang HJ: (Expression of liver-type fatty acid-binding protein and vascular endothelial growth factor and their correlation in human hepatocellular carcinoma). Nan Fang Yi Ke Da Xue Xue Bao 2007;27:318-21.
17. Ye Y, Huang A, Huang C, Liu J, Wang B, Lin K, et al.: Comparative mitochondrial proteomic analysis of hepatocellular carcinoma from patients. Proteomics Clin Appl 2013;7:403-15.
18. Fujii T, Nomoto S, Koshikawa K, Yatabe Y, Teshigawara O, Mori T, et al.: Overexpression of pituitary tumor transforming gene 1 in HCC is associated with angiogenesis and poor prognosis. Hepatology 2006;43:1267-75. (Pubitemid 43980105)
19. Shengbing Z, Feng LJ, Bin W, Lingyun G, Aimin H: Expression of KiSS-1 gene and its role in invasion and metastasis of human hepatocellular carcinoma. Anat Rec (Hoboken) 2009;292:1128-34.
20. Sprenkle P, Russo P: Molecular markers for ischemia, do we have something better then creatinine and glomerular filtration rate? Arch Esp Urol 2013;66:99-114.
21. Hammamieh R, Chakraborty N, Das R, Jett M: Molecular impacts of antisense complementary to the liver fatty acid binding protein (FABP) mRNA in DU 145 prostate cancer cells in vitro. J Exp Ther Oncol 2004;4:195-202. (Pubitemid 39557170)
22. Bioulac-Sage P, Balabaud C, Zucman-Rossi J: Subtype classification of hepatocellular adenoma. Dig Surg 2010;27:39-45.
23. Bioulac-Sage P, Rebouissou S, Thomas C, Blanc JF, Saric J, Sa Cunha A, et al.: Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology 2007;46:740-8. (Pubitemid 47436120)
24. Pontoglio M, Barra J, Hadchouel M, Doyen A, Kress C, Bach JP, et al.: Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. Cell 1996;84:575-85. (Pubitemid 26071738)
25. Akiyama TE, Ward JM, Gonzalez FJ: Regulation of the liver fatty acid-binding protein gene by hepatocyte nuclear factor 1alpha (HNF1alpha). Alterations in fatty acid homeostasis in HNF1alpha-deficient mice. J Biol Chem 2000;275:27117-22.
26. Zeng X, Lin Y, Yin C, Zhang X, Ning BF, Zhang Q, et al.: Recombinant adenovirus carrying the hepatocyte nuclear factor-1alpha gene inhibits hepatocellular carcinoma xenograft growth in mice. Hepatology 2011;54:2036-47.
27. Shim JH, Kang HJ, Han S, Lee YJ, Lee SG, Yu E, et al.: Prognostic Value of Hepatocyte Nuclear Factors 4alpha and 1alpha Identified by Tissue Microarray in Resectable Hepatocellular Carcinoma. Journal of gastroenterology and hepatology 2013.28
28. Wang G, Chen QM, Minuk GY, Gong Y, Burczynski FJ: Enhanced expression of cytosolic fatty acid binding protein and fatty acid uptake during liver regeneration in rats. Mol Cell Biochem 2004;262:41-9. (Pubitemid 39158053)